Carter Bankshares’ Q2 2026: Insurance Windfall, Portfolio Shuffle Lift Earnings—but What Happens Next?

Executive snapshot

The quarter ending June 30, 2026 delivered a mixed earnings cadence for Carter Bankshares, Inc. (NASDAQ: CARE). Net income for the second quarter was $28.9 million, translating to $1.31 in diluted earnings per share (EPS). That sits alongside a prior quarter’s outsized net income of $85.8 million and $3.88 diluted EPS for Q1 2026, and comparably modest results of $8.5 million and $0.37 diluted EPS for Q2 2025.

On the core line, net interest income totaled $40.0 million in Q2 2026, up from $35.9 million in Q1 2026 and $32.4 million in Q2 2025. The six months ended June 30, 2026 produced net income of $114.7 million, or $5.18 diluted EPS, versus $17.5 million and $0.76 diluted EPS for the same period in 2025. Adjusted net income for the six months was $20.2 million in 2026, compared with $16.6 million in 2025.

In short, CARE’s headline metric was buoyed by a sizable nonrecurring lift, while the “core” engine—loan growth and net interest income—showed a healthier trajectory, aided by a higher net interest margin (NIM) this quarter.

One-off transactions and near-term earnings mix

A significant portion of the six-month period’s earnings is explained by nonrecurring gains. The Company reported aggregate nonrecurring gains of roughly $100.9 million in the first half of 2026, reflecting strategic asset actions and liability management. The lion’s share of this was driven by the Insurance Transaction, a sale of a membership interest in Bearing Insurance Group, LLC, completed May 1, 2026.

Net gains from the Insurance Transaction were reported as a pre-tax $35.9 million, and the transaction was accretive to diluted EPS by about $1.30 for the quarter. The Insurance Transaction also contributed to a tangible book value per share uplift of around $1.28.

By contrast, other balance-sheet moves—what CARE labels the Portfolio Repositioning—generated a pre-tax loss of $12.5 million in the second quarter. The net effect of the portfolio repositioning reflects the bank’s aim to tilt the yield curve toward higher-quality assets, while preserving capital and liquidity for loan growth.

Portfolio Repositioning details

During the Portfolio Repositioning, CARE sold $139.4 million of book-value securities available-for-sale with a weighted-average yield of 2.28%, representing about 18.7% of the securities portfolio. In parallel, the bank purchased approximately $88.5 million of securities with a weighted-average yield around 5.27%. All purchases were rated AAA or AA by recognized rating agencies. Management indicates the remaining cash proceeds will be used to fund organic loan growth through the balance of 2026.

Operational highlights and loan book evolution

Financial highlights for the three months ended June 30, 2026 include: total portfolio loans increased by about $6.1 million from March 31, 2026, even as roughly $132.6 million in commercial real estate loan payoffs occurred in the quarter. Net interest income rose to $40.0 million, up $4.1 million QoQ and $7.6 million year-over-year, while net interest margin expanded to 3.38% in Q2 2026—up 31 basis points from the prior quarter and 58 basis points versus the year-ago quarter.

The company also noted ongoing repositioning in the credit book, including a reduction of a large nonperforming relationship earlier in 2026 via the Loan Sale Transaction. Nonperforming loans increased by $13.6 million in the quarter, a development analysts will want to watch as it relates to future charge-offs and credit-quality dynamics.

What this implies for CARE and peers

From a financial-architecture standpoint, CARE is juggling a blend of nonrecurring gains, core earnings, and a deliberate balance-sheet reshaping. The Insurance Transaction and the Loan Sale Transaction collectively produced a sizable near-term earnings tailwind, masking underlying core profitability in the quarter. The six-month results suggest a stronger earnings baseline, even as the company acknowledges the importance of organic loan growth and asset-yield optimization to sustain earnings power beyond one-offs.

For sector peers, CARE’s strategy underscores a familiar playbook in a difficult rate environment: monetize noncore assets, reposition the securities portfolio toward higher-yielding, high-quality assets, and push for loan growth to lift net interest income and NIM. If other banks pursue similar asset-lightening moves, we could see a wave of balance-sheet reorganizations that temporarily boost EPS and tangible book value per share—without necessarily altering the long-term earnings trajectory.

Outlook and questions to watch

Key questions for investors and observers include: Will the early 2026 nonrecurring gains translate into a sustained earnings profile, or will future quarters revert to a more normalized rhythm? How durable is the NIM improvement, given ongoing balance-sheet repositioning and loan growth? And how will sector peers respond—will we see a broader pattern of asset sales and yield-enhancing purchases that recalibrate the competitive landscape?

In the near term, CARE’s reported EPS of $1.31 for Q2 2026 sits in contrast to the six-month EPS of $5.18, which reflects the consolidation of one-off gains across the period. Analysts watching the EPS consensus and any potential earnings surprise from upcoming quarters will likely weigh the durability of the core earnings contribution—net interest income, loan growth, and margin—against the tailwinds and headwinds from balance-sheet optimization.

Takeaways for investors

• CARE delivered a notable Q2 2026 EPS of 1.31, with net income of $28.9 million, alongside substantial six-month gains from nonrecurring events.
• The Insurance Transaction provided a meaningful pre-tax gain and lifted tangible book value per share, but the accompanying pre-tax nature means core earnings may look different on a normalized basis.
• The Portfolio Repositioning produced a short-term negative, offset by aims to improve asset yields and balance-sheet positioning for future earnings power.
• Net interest income and NIM improved in Q2 2026, supported by a loan portfolio that grew modestly despite sizable CRE payoffs.
• Analysts will be assessing how CARE’s actions affect revenue forecasts, EPS consensus, and the sustainability of the earnings power as the year progresses.